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The growing global type 2 diabetes mellitus (T2DM) 
epidemic has shown no signs of slowing down. The 
parallel increase in obesity implicates unhealthy diet 
and sedentary lifestyle as main factors, which are fast 
becoming a way of life. Environmental and genetic 
factors have offered alternative perspectives to the 
diabetes front, although the aging population could be a 
much simpler explanation. Little has remained constant 
and a great deal more is being discovered. 
  A particular concern of the T2DM epidemic 
currently is the preponderance towards the developing 
countries and the younger age groups. Asia has been 
identified to be at the epicentre of the diabetes turmoil, 
significantly affected, whereby patients are diagnosed 
younger and thinner in comparison to their Caucasian 
counterparts [1]. Malaysia has observed an alarming 
rise in the prevalence of T2DM over the past and recent 
decades. The latest Malaysian National Health and 
Morbidity Survey (NHMS) in 2015 reported the 
prevalence of T2DM among adults above 18 years to be 
17.5% [2]. This has been a steady rise from 15.2% in 
2011 and 14.9% in 2006 [3,4]. More alarmingly, the 
same national survey in 2015 showed the prevalence of 
obesity among adult Malaysians to be 30.6%, which is 
more than double the 2014 world prevalence of 13% 
[5]. Differences within the ethnic groups have been 
observed but not fully understood. Based on that latest 
survey, the highest prevalence was detected among the 
Indians of 22.1% (95% CI: 19.2, 25.3), whilst the 
Malays had a prevalence of 14.6% (95% CI: 13.8, 
15.5), the Chinese had 12.0% (95% CI: 10.7, 13.5), and 
finally the Bumiputras had 10.7% (95% CI: 8.8, 13.0) 
[2].  
  Diabetes is a major health concern whereby 
many are killed but more are debilitated. Cure remains 
impossible and progression of the disease over time is 
certain.  The International Diabetes Federation (IDF) 
has estimated that twice as many people have died 
because of diabetes through premature cardiovascular 
deaths in comparison to HIV–AID [6]. The National 
Cardiovascular Disease- Acute Coronary Syndrome 
(NCVD-ACS) registry reported a mean age of between 
55.9 to 59.1 years among Malaysians experiencing ACS 
in comparison to most of the developed countries, 
which had mean ages of between 63.4 to 68 years [7]. 
In addition, microvascular complications has placed 
Malaysia among the top 5 countries with the highest 
prevalence of end stage renal disease (ESRD) in the 
world secondary to diabetic nephropathy, attributed to 
in 61% of patients initiating renal replacement therapy, 
according to national data [8]. 
  After decades of discovering the disease, new 
data surrounding diabetes continue to emerge, 
underscoring its complexity.  What was previously 
known as the triad of insulin resistance, β-cell 
dysfunction, and impaired hepatic glucose production 
has evolved to the more elegant concept of the ominous 
octet. The complexity of the pathophysiology of the 
disease is enhanced with the additional theories on renal 
glucose reabsorption, abnormal glucagon secretion, the 
incretin effects, increased lipolysis and neurotransmitter 
dysfunction [9]. This theory affects many aspects of 
diabetes as it opened up a field of potential therapeutic 
targets aimed to normalize glycaemia and achieve a 
target, which has been debatable over time.   
  Billions of dollars have been invested in the 
development of the various aspects of management of 
this complex disease.  As the financial burden 
surrounding diabetes continues to rise, the questions 
remain- Have we actually got it right? Could the 
growing figures above indicate that our understanding 
Treatment of Type 2 Diabetes Mellitus – What is the Direction? 
 
Rohana Abdul Ghani 
 
Faculty of Medicine, Universiti Teknologi MARA (UiTM), Selangor, Malaysia 
 
  Treating T2DM- What is the Direction? 
 
 
Vol 2(1) (2017) 4-7 | jchs-medicine.uitm.edu.my | eISSN-0127-984X 
 
5 
of the disease is flawed as are our theories on the 
management? What is the direction of T2DM? 
 
Treatment options in diabetes  
 
Diabetes is a lifelong progressive illness, associated 
with complications that could only worsen despite 
current treatments. Management of diabetes has 
received immense amount of attention in recent years 
due to many factors. The worsening global figure, the 
recognized complications, increased public awareness 
and intensified health campaigns are among some 
contributing factors. It has also been mostly driven by 
the pharmaceutical industry with the growing 
armamentarium of anti-diabetic medications, 
particularly over the past two decades.  The aim of 
T2DM treatment has fortunately not evolved to 
anything other than to reduce the risk of development of 
diabetic complications. Fortunately, recent guidelines 
have placed a lot of emphasis on the need to minimise 
side effects, improve quality of life and ultimately 
prolong life.    
  The ominous octet theory paved the way to 
multiple new therapeutic options, which could target 
various pathways and thus may prove to be more 
potent. Furthermore, it suggested that treatment of 
T2DM should utilize combination therapies to address 
many abnormalities simultaneously, synergistically or 
otherwise.  It also suggested that therapeutic agents are 
created not merely to reduce HbA1C but more so to 
treat identified pathophysiological anomalies. Finally, 
treatment must be initiated early to prevent progressive 
β-cell failure [9].   
  Among the more recent buzz in anti-diabetic 
treatments is the discovery of the new sodium-glucose 
co-transporter 2 (SGLT-2) inhibitors. This group of 
drugs has challenged the conventional understanding of 
glycosuria being harmful and instead lowers glucose 
level by promoting renal glucose excretion via 
inhibition of glucose reabsorption at the proximal 
tubules. Clinical studies have demonstrated 
improvements in HbA1c by between 0.32% and 1.17% 
with the SGLT2 inhibitors, efficacies of which are 
dose-dependent and determined by baseline glycaemic 
levels [10]. Added benefits include weight reduction 
due to glucose loss and blood pressure reductions 
possibly due to fluid loss and effects on the juxta-
glomerular apparatus.  
  The injectable Glucagon-like Peptide 1 (GLP-
1) agonist is another anti-diabetic medication approved 
for the treatment of T2DM. It is an incretin mimetic, 
acting through a glucose-dependent mechanism to 
reduce glucagon secretion, increase satiety and delay 
gastric emptying. The mean HbA1c reduction ranged 
between 0.7% and 1.7%, dependent on the administered 
dose [10]. Liraglutide has demonstrated lower rate of 
cardiovascular endpoints among patients with T2DM 
compared to placebo, accompanied by minimal 
difference in glycaemic control (mean difference of 
−0.40% (95% CI, −0.45 to −0.34) [11]. Another GLP-1 
agonist, Semaglutide also showed improvement in 
kidney end points, despite increased risk of retinopathy 
[12]. The added benefit of significant weight loss has 
led to added indication as a weight losing therapy, 
albeit at a higher dose.  
  However, each therapeutic group has 
particular adverse effects. The SGLT-2 inhibitors have 
evidently high risk for genital mycotic infections with 
reported hypoglycaemia only in combination with 
sulfonylurea and insulin. Other side effects include 
diabetic ketoacidosis and bone fractures, controversial 
to whether they are of class effect or drug-specific [13]. 
 
Treatment plan - Reduction of HbA1c or 
cardiovascular risk reduction? 
 
Previous landmark clinical trials have provided 
evidence that glycated haemoglobin (HbA1c) is a 
reliable tool for the measurement of glycaemic control. 
Lower HbA1c is pivotal in reducing macrovascular 
complications, albeit less evident with microvascular 
complications [14]. Evidence-based medicine has 
aggressively driven the glycaemic target down to near 
normal levels of HbA1c less than 6%, which has 
subsequently shown deleterious effects rather than 
benefit [15], prompting caution in overzealous 
tightening of glycaemia. Instead, the use of other drugs 
including statins and renin-angiotensin system 
inhibitors had provided more impactful data on 
lowering of cardiovascular risks in this group of high-
risk patients. Emergence of more robust clinical trials in 
recent years is indeed consequential of this 
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development. Trials are designed to assess 
cardiovascular safety of the anti-diabetic medications 
rather than the glycaemic effects, leading to further 
understanding and debate on the role of HbA1c in 
determining macrovascular and microvascular 
outcomes. The trials have to date, suggested that the 
means of how the reduction in HbA1c is achieved, 
could play a more important role in determining the 
final clinical outcome. 
  The year 2016 had provided us with a lot of 
exciting new data in diabetes. The widely discussed 
EMPA-REG study has shown significant reductions in 
cardiovascular deaths (38% relative risk reduction) and 
kidney outcome (relative risk reduction of 39%) with 
empagliflozin despite minimal changes in glycemic 
control throughout a median follow up of 3.1 years 
[16]. Similarly, the LEADER clinical trial concluded 
that Liraglutide compared to placebo, lowered major 
cardiac outcome risks by 13%.  It also reduced 15% risk 
for all-cause death and 22% of CV death, over a, 
relatively, short study duration of 3.8 years. 
  Combination therapies have gained 
momentum towards the forefront of T2DM 
management, with the aim to increase efficacy whilst 
minimizing side effects. The combination of GLP-1 
agonists and SGLT-2 inhibitors is an ideal match for 
multiple reasons. Both agents have dependable 
efficacies in glucose and weight-lowering effects,  
which are achieved through contrasting pathways. 
DURATION-8 trial studied the combination therapy of 
exenatide and dapagliflozin in T2DM patients who 
were inadequately controlled by metformin 
monotherapy [17]. The data from the study showed that 
the regime was well tolerated with minimal 
hypoglycaemic events. There was significant 
improvements in glycaemic measurements with HbA1c 
reduction of 1.95% from baseline compared to 1.58% 
and 1.37% with exenatide or dapagliflozin alone, 
respectively, p<0.01. Similarly, there was greater 
weight loss with the combination therapy versus 
monotherapy (–3.4 kg versus –1.5 kg and –2.2 kg, 
respectively; p<0.01) accompanied by significant 
reductions of systolic blood pressure [17]. Thus, the 
combination therapy of GLP-1 agonist and SGLT2 
inhibitor hold immense potential for the treatment of 
T2DM, specifically in obese patients and those with 
concomitant cardiovascular diseases.  
  The standard treatment for T2DM in almost all 
guidelines includes dietary changes, physical activities, 
and metformin followed by other anti-diabetic 
medications. Individualisation of patient care has been 
at the centre of T2DM management strategy. The 
American Diabetes Association/European Association 
for the Study of Diabetes and NICE treatment 
guidelines have emphasized that the choice of anti-
diabetic therapy must revolve around an appropriate 
glycaemic target, with ability of patients to adhere to 
the treatment plan while experiencing minimal to no 
side effects, at an affordable cost [13, 18]. Based on 
recent evidence-based data and updated guidelines, 
healthcare providers should consider the cardiovascular 
effects besides the specific side effects and 
hypoglycaemia risks of a particular medication to 
provide maximum benefit of the prescribed treatment 
plan to the patient. 
  However, other challenges are yet to be 
overcome. Durations of these clinical trials are 
relatively short and long-term adverse effects are 
currently unknown, especially on the risks of 
malignancy. Current global economic uncertainty is 
another major concern and cost effectiveness studies are  
needed to provide scientific rationale for this expensive 
combination option. The developments of newer agents 
continue to threaten the relevance of current and older 
medications. Finally, will HbA1c again manage to 
emerge champion and remain vital in the management 
process of diabetes? 
  In conclusion, anti-diabetic therapies have 
evolved over time. Many post-marketing, safety 
surveillance clinical trials have provided robust data 
beyond the initial aims of the studies. A lot of emphasis 
has been placed on the importance of reductions in 
cardiovascular and renal outcomes, which consequently 
diminish the reference towards glycaemic control. This 
has underscored more recent medications, mainly the 
SGLT2 inhibitors and GLP-1 agonists as the ideal 
choice of therapy. Despite the added cost, this might 
prove to be a more appropriate direction as selection of 
medications will be made based on a patient’s 
underlying comorbidities and cardiovascular risk 
factors, true individualization for a common illness. 
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